SiBone (NASDAQ:SIBN) Stock: Insider Jeffrey Dunn Sells 20,000 Shares

Key Points

• Director Jeffrey Dunn sold 20,000 SiBone shares for $417,800 at an average price of $20.89, reducing his stake by 55.47% to 16,057 shares.
• SiBone’s quarterly results beat estimates: its $0.08-per-share loss was narrower than the expected $0.13 loss, and revenue of $55.7 million topped the $55.31 million consensus.
• Shares rose 5% to $24.95 in Wednesday trading. Analysts’ average price target was $25, with a consensus rating of “Moderate Buy.”

SiBone (NASDAQ:SIBN - Get Free Report) Director Jeffrey Dunn sold 20,000 shares of the business's stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $20.89, for a total transaction of $417,800.00. Following the transaction, the director directly owned 16,057 shares in the company, valued at approximately $335,430.73. The trade was a 55.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

SiBone Stock Up 5.0%

Shares of SIBN stock traded up $1.18 on Wednesday, hitting $24.95. The stock had a trading volume of 2,186,969 shares, compared to its average volume of 637,019. The stock's 50 day moving average is $19.50 and its 200-day moving average is $16.48. The firm has a market capitalization of $1.11 billion, a price-to-earnings ratio of -80.48 and a beta of 0.64. SiBone has a 52-week low of $11.48 and a 52-week high of $25.92. The company has a debt-to-equity ratio of 0.20, a quick ratio of 7.55 and a current ratio of 9.15.

SiBone (NASDAQ:SIBN - Get Free Report) last released its quarterly earnings results on Monday, November 2nd. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.05. SiBone had a negative net margin of 6.20% and a negative return on equity of 7.62%. The firm had revenue of $55.70 million for the quarter, compared to the consensus estimate of $55.31 million. As a group, research analysts expect that SiBone will post -0.40 earnings per share for the current year.

SiBone News Roundup

Here are the key news stories impacting SiBone this week:

• Positive Sentiment: Q3 results beat estimates. SI-BONE reported a loss of $0.08 per share, smaller than the $0.13 loss analysts expected, while revenue of $55.7 million narrowly topped the $55.3 million estimate. The quarterly loss also improved from $0.11 per share a year earlier. Si-Bone Reports Q3 Loss, Tops Revenue Estimates
• Positive Sentiment: UBS raised its price target and kept a Buy rating. UBS lifted its target from $25 to $26, implying about 4.3% upside from the cited $24.92 share price. UBS price-target update
• Neutral Sentiment: 2026 revenue guidance was essentially in line. SI-BONE forecast revenue of $231 million to $233 million, bracketing the $232.2 million consensus estimate. TD Cowen raised its target from $20 to $23 and reiterated Buy, although that target is below the cited current share price. TD Cowen analyst update
• Negative Sentiment: Two executives sold shares. SVP Michael Pisetsky sold 29,665 shares for about $656,000, reducing his holdings by 15.28%; insider Anshul Maheshwari sold 3,738 shares for about $84,000. Such sales can weigh on sentiment, though both retained substantial holdings. SI-BONE insider sales

Hedge Funds Weigh In On SiBone

Large investors have recently bought and sold shares of the business. First Light Asset Management LLC boosted its position in shares of SiBone by 51.8% in the 2nd quarter. First Light Asset Management LLC now owns 8,127,985 shares of the company's stock valued at $132,649,000 after purchasing an additional 2,774,795 shares during the period. Granahan Investment Management LLC grew its position in SiBone by 97.6% during the 1st quarter. Granahan Investment Management LLC now owns 1,739,097 shares of the company's stock worth $21,965,000 after purchasing an additional 858,942 shares in the last quarter. Paradigm Capital Management Inc. NY grew its position in SiBone by 113.3% during the 1st quarter. Paradigm Capital Management Inc. NY now owns 1,126,500 shares of the company's stock worth $14,228,000 after purchasing an additional 598,300 shares in the last quarter. Dimensional Fund Advisors LP grew its position in SiBone by 41.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 618,939 shares of the company's stock worth $7,816,000 after purchasing an additional 182,465 shares in the last quarter. Finally, Renaissance Technologies LLC raised its stake in SiBone by 101.6% during the 1st quarter. Renaissance Technologies LLC now owns 472,619 shares of the company's stock valued at $5,969,000 after purchasing an additional 238,219 shares during the period. Institutional investors own 98.11% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on SIBN. Truist Financial increased their target price on SiBone from $23.00 to $25.00 and gave the company a "buy" rating in a research note on Wednesday, October 14th. Citigroup restated a "market outperform" rating on shares of SiBone in a research note on Tuesday. UBS Group upped their price target on shares of SiBone from $25.00 to $26.00 and gave the company a "buy" rating in a report on Tuesday. Weiss Ratings raised shares of SiBone from a "sell (e+)" rating to a "sell (d-)" rating in a report on Thursday, August 20th. Finally, TD Cowen raised their price objective on shares of SiBone from $20.00 to $23.00 and gave the stock a "buy" rating in a report on Tuesday. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $25.00.

About SiBone

SI-BONE, Inc NASDAQ: SIBN is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.

Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.